Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy Study of the Effect of Budesonide on Emphysema

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: October 4, 2005
Last updated: January 21, 2011
Last verified: January 2011

To assess the effect of up to 4 years treatment with budesonide on progression of emphysema in patients with Chronic Obstructive Lung Disease.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Pulmicort (budesonide) Turbuhaler
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effect of Inhaled Corticosteroids on the Development of Emphysema in Smokers Assessed by Computed Tomography (CT).

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The primary variable in the study was change in lung density measured by Computed Tomography annually.

Secondary Outcome Measures:
  • Decline in lung Function (FEV1) and exacerbation rate were measured biannually and decline in diffusion capacity (TLCO) annually.

Estimated Enrollment: 240
Study Start Date: July 1999
Study Completion Date: February 2004

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical Chronic Obstructive Pulmonary Disease diagnosis
  • smoker

Exclusion Criteria:

  • No exacerbation within the last 30 days
  • no long term use of oral corticosteroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00232674

Research Site
Gentofte, Denmark
Sponsors and Collaborators
Study Director: Astra Zeneca AstraZeneca
  More Information

No publications provided Identifier: NCT00232674     History of Changes
Other Study ID Numbers: AD-004-0001
Study First Received: October 4, 2005
Last Updated: January 21, 2011
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by AstraZeneca:
Chronic Obstructive Pulmonary Disease

Additional relevant MeSH terms:
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases processed this record on March 03, 2015